Sirolimus for non-progressive NF1-associated plexiform neurofibromas: An NF clinical trials consortium phase II study

Pediatric Blood and Cancer

Volumn 61, Issue 6, 2014, Pages 982-986

  Weiss, Brian ^a   Widemann, Brigitte C ^b   Wolters, Pamela ^b   Dombi, Eva ^b   Vinks, Alexander A ^a   Cantor, Alan ^c   Korf, Bruce ^c   Perentesis, John ^a   Gutmann, David H ^d   Schorry, Elizabeth ^a   Packer, Roger ^e   Fisher, Michael J ^f  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Clinical trials; MTOR; Neurofibromatosis; New agents; Solid; Tumors

Indexed keywords

NEUROFIBROMIN; RAPAMYCIN; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ALLERGIC REACTION; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; FEMALE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LYMPHOMA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROFIBROMA; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RASH; SCORING SYSTEM; SELF REPORT; SIDE EFFECT; STEADY STATE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DIARRHEA; EMOTIONS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROFIBROMA, PLEXIFORM; NEUROFIBROMATOSIS 1; PAIN MEASUREMENT; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; QUESTIONNAIRES; SIROLIMUS; SOFT TISSUE NEOPLASMS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84901725467     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24873     Document Type: Article

References (39)

1. Korf BR. Plexiform neurofibromas. Am J Med Genet 1999; 89:31-37.
2. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist 2000; 5:477-485.
3. Needle MN, Cnaan A, Dattilo J, et al. Prognostic signs in the surgical management of plexiform neurofibroma: The Children's Hospital of Philadelphia experience, 1974-1994. J Pediatr 1997; 131:678-682.
4. Dombi E, Solomon J, Gillespie AJ, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight. Neurology 2007; 68:643-647.
5. Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988; 111:1355-1381.
6. Waggoner DJ, Towbin J, Gottesman G, et al. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Am J Med Genet 2000; 92:132-135.
7. Plotkin SR, Bredella MA, Cai W, et al. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PloS ONE 2012; 7:e35711.
8. Kim A, Gillespie A, Dombi E, et al. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. Neurology 2009; 73:1273-1279.
9. Nguyen R, Ibrahim C, Friedrich RE, et al. Growth behavior of plexiform neurofibromas after surgery. Genet Med 2013; 15:691-697.
10. Johannessen CM, Reczek EE, James MF, et al. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 2005; 102:8573-8578.
11. Dasgupta B, Yi Y, Chen DY, et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 2005; 65:2755-2760.
12. Houghton PJ, Huang S. mTOR as a target for cancer therapy. Curr Top Microbiol Immunol 2004; 279:339-359.
13. Weber JD, Gutmann DH. Deconvoluting mTOR biology. Cell Cycle 2012; 11:236-248.
14. Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Nat Rev Cancer 2004; 4:335-348.
15. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: A review of the evidence. Kidney Int 2001; 59:3-16.
16. Johansson G, Mahller YY, Collins MH, et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther 2008; 7:1237-1245.
17. Hegedus B, Banerjee D, Yeh TH, et al. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res 2008; 68:1520-1528.
18. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37:405-415.
19. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59:490-498.
20. Scott JR, Courter JD, Saldana SN, et al. Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis Type 1. Ther Drug Monit 2013; 35:332-337.
21. Solomon J, Warren K, Dombi E, et al. Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput Med Imag Graph 2004; 28:257-265.
22. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: Reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med Care 2001; 39:800-812.
23. Varni JW, Burwinkle TM, Seid M. The PedsQL as a pediatric patient-reported outcome: Reliability and validity of the PedsQL measurement model in 25, 000 children. Expert Rev Pharmacoecon Outcomes Res 2005; 5:705-719.
24. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 1993; 11:570-579.
25. Cella D, Nowinski CJ. Measuring quality of life in chronic illness: The functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil 2002; 83:S10-S17.
26. Varni JW, Thompson KL, Hanson V. The Varni/Thompson pediatric pain questionnaire. I. Chronic musculoskeletal pain in juvenile rheumatoid arthritis. Pain 1987; 28:27-38.
27. Melzack R. The short-form McGill pain questionnaire. Pain 1987; 30:191-197.
28. Cohen LL, Lemanek K, Blount RL, et al. Evidence-based assessment of pediatric pain. J Pediatr Psychol 2008; 33:939-955; discussion 956-957.
29. Jensen MP. The validity and reliability of pain measures in adults with cancer. J Pain 2003; 4:2-21.
30. Hilliard ME, Lawrence JM, Modi AC, et al. Identification of minimal clinically important difference scores of the pediatric quality of life inventory in children, adolescents, and young adults with Type 1 and Type 2 diabetes. Diabetes Care 2013; 36:1891-1897.
31. Ringash J, O'Sullivan B, Bezjak A, et al. Interpreting clinically significant changes in patient-reported outcomes. Cancer 2007; 110:196-202.
32. Varni JW, Burwinkle TM, Seid M, et al. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr 2003; 3:329-341.
33. Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: A reanalysis of two clinical trials of postoperative pain. J Pain 2003; 4:407-414.
34. Lee JS, Hobden E, Stiell IG, et al. Clinically important change in the visual analog scale after adequate pain control. Acad Emerg Med 2003; 10:1128-1130.
35. Wu J, Dombi E, Jousma E, et al. Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox);DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer 2012; 58:173-180.
36. Johannessen CM, Johnson BW, Williams SMG, et al. TORC1 is essential for NF1-associated malignancies. Curr Biol 2008; 18:56-62.
37. Halloran J, Hussong SA, Burbank R, et al. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience 2012; 223:102-113.
38. Lang UE, Heger J, Willbring M, et al. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement. Transplant Proc 2009; 41:4285-4288.
39. Wolters PL, Martin S, Merker V, et al. Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. Neurology 2013; in press.